News >

FDA Grants Atezolizumab Combo Breakthrough Designation for Frontline HCC

Jason M. Broderick @jasoncology
Published: Wednesday, Jul 18, 2018

Dr. Sandra Horning
Sandra Horning, MD
The FDA has granted atezolizumab (Tecentriq) a breakthrough therapy designation for use in combination with bevacizumab (Avastin) as a first-line treatment for patients with advanced or metastatic hepatocellular carcinoma (HCC).

The ongoing phase III IMbrave150 study (NCT03434379) is comparing atezolizumab/bevacizumab with sorafenib (Nexavar) in the frontline setting for patients with locally advanced or metastatic HCC.
Stein S, Pishvaian MJ, Lee MS, et al. Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC). J Clin Oncol. 2018;36 (suppl; abstr 4074).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication